The quest for alternative drugs to the well-known cisplatin and its derivatives, which are still used in more than 50% of the treatment regimes for patients suffering from cancer, is highly needed.1,2 Despite their tremendous success, these platinum compounds suffer from two main disadvantages: they are inefficient against platinum-resistant tumors, and they have severe side effects such as nephrotoxicity. The latter drawback is the consequence of the fact that the ultimate target of these drugs is ubiquitous: It is generally accepted that Pt anticancer drugs target DNA, which is present in all cells.3,4 Furthermore, as a consequence of its particular chemical structure, cisplatin in particular offers little possibility for rational improvements to increase its tumor specificity and thereby reduce undesired side effects.

In this context, organometallic compounds, which are defined as metal complexes containing at least one direct, covalent metal−carbon bond, have recently been found to be promising anticancer drug candidates. Organometallics have a great structural variety (ranging from linear to octahedral and even beyond), have far more diverse stereochemistry than organic compounds (for an octahedral complex with six different ligands, 30 stereoisomers exist!), and by rational ligand design, provide control over key kinetic properties (such as hydrolysis rate of ligands). Furthermore, they are kinetically stable, usually uncharged, and relatively lipophilic and their metal atom is in a low oxidation state. Because of these fundamental differences compared to “classical coordination metal complexes”, organometallics offer ample opportunities in the design of novel classes of medicinal compounds, potentially with new metal-specific modes of action. Interestingly, all the typical classes of organometallics such as metallocenes, half-sandwich, carbene-, CO-, or π-ligands, which have been widely used for catalysis or biosensing purposes, have now also found application in medicinal chemistry (see Figure ​Figure11 for an overview of these typical classes of organometallics).



Figure 1

Summary of the typical classes of organometallic compounds used in medicinal chemistry.



In this Perspective, we report on the recent advances in the discovery of organometallics with proven antiproliferative activity. We are emphasizing those compounds where efforts have been made to identify their molecular target and mode of action by biochemical or cell biology studies. This Perspective covers more classes of compounds and in more detail than a recent tutorial review by Hartinger and Dyson.(5) Furthermore, whereas recent reviews and book contributions attest to the rapid development of bioorganometallic chemistry in general,6,7 this Perspective focuses on their potential application as anticancer chemotherapeutics. Another very recent review article categorizes inorganic anticancer drug candidates by their modes of action.(8) It should be mentioned that a full description of all currently investigated types of compounds is hardly possible anymore in a concise review. For example, a particularly promising class of organometallic anticancer compounds, namely, radiolabeled organometallics, has been omitted for space limitations. Recent developments of such compounds have been reviewed in detail by Alberto.(9)

http://pubs.acs.org/doi/pdf/10.1021/jm100020w

Organometallic Anticancer Compounds

In undergraduate level organometallic chemistry courses students are usually taught that organometallic compounds are toxic and unstable in air and water. While this is true of many complexes, some are also non-toxic and stable in air and water. Indeed, bioorganometallic chemistry, the study of biomolecules or biologically active molecules that contain at least one carbon directly bound to a metal, is a thriving subject, and air and water stability is a general pre-requisite. This interdisciplinary field is located at the borderline between chemistry, biochemistry, biology and medicine. In this tutorial review, various aspects of bioorganometallic chemistry are introduced, with the main emphasis on medicinal organometallic compounds. Organometallic therapeutics for cancer, HIV and malaria and other medicinal applications are described. It is also shown how rational ligand design has led to new improved therapies much in the same way that an organometallic chemist working in catalysis will design new ligands for improved activities.

Bioorganometallic chemistry—from teaching paradigms to medicinal applications

This tutorial review compiles the advances that have been achieved in using transition metal complexes containing N-heterocyclic carbene ligands as components for materials. Applications of metal carbene complexes in fields different from catalysis are remarkably scarce. During the last few years, promising results have been accomplished in particular by utilizing such complexes as antimicrobial and cytotoxic agents, as photoactive sites in luminescent materials, for self-assembly into liquid crystalline materials and metallosupramolecular structures, and as synthons for molecular switches and conducting polymeric materials. These initial achievements clearly underline the great potential of N-heterocyclic carbene complexes in various fields of materials science.

/pdf/beyond-catalysis-n-heterocyclic-carbene-complexes-as-3z9cgukcrj.pdf

Beyond catalysis: N-heterocyclic carbene complexes as components for medicinal, luminescent, and functional materials applications.

The discovery of cisplatin's antitumor activity in 1969 prompted the search for novel metal-containing complexes as potential anticancer drugs. Among these novel complexes, metal N-heterocyclic carbene (NHC) complexes have recently gained considerable attention because they perfectly fit prerequisites for efficient drug design and fast optimization. Moreover, most of them have shown higher cytotoxicity than cisplatin. This review describes the advances that have been achieved in using transition metal (Ag, Au, Pt, Pd, Cu, Ni, and Ru) complexes containing NHC ligands as antitumor agents. Their modes of action at the cellular lever are further discussed. All these initial achievements clearly demonstrate the great potential of metal–NHC complexes as antitumor agents.

Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs

https://pubs.rsc.org/en/content/articlepdf/2013/cc/c3cc41143e

Exploration of the medical periodic table: towards new targets

p-Methoxybenzyl-substituted and benzyl-substituted N-heterocyclic carbene (NHC) [(3a-c) and (6a-c)] precursors were synthesised from the reaction of 1H-imidazole (1a), 4,5-dichloro-1H-imidazole (1b), and 1H-benzimidazole (1c) with p-methoxybenzyl bromide (2) and benzyl bromide (5). These NHC precursors were then treated with silver(I) acetate to yield the NHC-silver complexes [1,3-bis(4-methoxybenzyl)-imidazol-2-ylidene]silver(I) acetate (4a), [4,5-dichloro-1,3-bis(4-methoxybenzyl)imidazol-2-ylidene]silver(I) acetate (4b), [1,3-bis(4-methoxybenzyl)benzimidazol-2-ylidene]-silver(I) acetate (4c), (1,3-dibenzylimidazol-2-ylidene)silver(I) acetate (7a), (1,3-dibenzyl-4,5-dichloroimidazol-2-ylidene)-silver(I) acetate (7b), and (1,3-dibenzylbenzimidazol-2-ylidene)silver(I) acetate (7c), respectively. The NHC precursor 3c, four NHC-silver complexes 4c and 7a-c were characterised by single-crystal X-ray diffraction method. The preliminary antibacterial activity of all the compounds was studied against Gram-negative bacteria Escherichia coli, and Gram-positive bacteria Staphylococcus aureus using the Kirby-Bauer disk-diffusion method. Almost all the NHC-silver complexes have shown high antibacterial activity compared to the NHC precursors. In addition, the NHC-silver complexes had their cytotoxicity investigated through MTT-based preliminary in vitro testing on the Caki-1 cell lines in order to determine their IC 50 values. NHC-silver complexes 4a-c and 7a-c were found to have IC 50 values of 7.3 (+/-6), 12.7 (+/-3), 25.2 (+/-5), 2.5 (+/-3), 10.8 (+/-4) and 12.5 (+/-4) μM respectively on the Caki-1 cell line.

Synthesis, Cytotoxicity and Antibacterial Studies of p-Methoxybenzyl-Substituted and Benzyl-Substituted N-Heterocyclic Carbene-Silver Complexes

Novel organotin antibacterial and anticancer drugs

Outside of platinum and ruthenium anticancer drugs, there is significant unexplored space for further metal-based drugs that target cancer, such as titanocene dichloride. One of these promising drug candidates is bis-[(p-methoxybenzyl)cyclopentadienyl]titanium(IV) dichloride (titanocene Y, 1), which is accessible via the hydridolithiation reaction of 6-anisylfulvene and subsequent transmetallation with titanium tetrachloride. Compound 1 exhibits an IC50 value of 21 mm toward the LLC-PK cell line, which has proven to be a good mimic of a kidney carcinoma cell line and a reliable tool for the optimisation of titanocenes against this type of cancer. Additionally, the antiproliferative activity of 1 and other titanocenes has been studied in 36 human tumour cell lines and against explanted human tumours. 6] These in vitro and ex vivo experiments showed that renal cell cancer is the prime target for this novel class of titanocenes, but there is significant activity against ovarian, prostate, cervical, lung, colon, and breast cancers as well. Furthermore, titanocene derivatives give a positive immune response by up-regulating the number of natural killer (NK) cells in mice. These results were underscored by initial mechanistic studies of the effects of these titanocenes on apoptosis and the apoptotic pathway in prostate and cervical cancer cells. Recently, animal studies demonstrated the successful treatment of mice bearing xenografted A431, Caki-1, and MCF-7 tumours with 1. Herein the synthesis and initial cytotoxicity studies of titanocene oxalate and oxali-titanocene Y (2) are presented. The structures and syntheses of 1 and 2 are shown in Scheme 1. A simple anion-exchange reaction in THF employing silver oxalate eliminates insoluble silver chloride and produces 2 or titanocene oxalate. An X-ray crystallographic study established the molecular structure of 2 (Figure 1). Despite the addition of the oxalate bidentate ligand in replacement of the two chlorides on the titanium centre, there is almost no apparent variance in the molecular structures of 1 and 2. The length of the bond between the titanium centre and the carbon atoms of the cyclopentadienide rings are very similar for both 1 and 2. They vary from 2.34 to 2.41 C for 1 and from 2.33 to 2.40 C for 2. Very slight differences can be observed in comparing the titanium centroid distances in 1 (2.06 C) and 2 (2.04 C). The centroid–titanium–centroid angle is 130.78 for 1, whereas the corresponding angle in 2 is 134.88. This widening goes nicely with the more blade-like shape of the oxalate anion, compared with the spherical chloride anions. As expected, the average titanium–chloride bond in 1 is considerably longer (2.37 C) than the average titanium–oxygen bond in 2 (1.99 C). The average carbon–oxygen single and double bonds in 2 are, with 1.30 C and 1.21 C, quite close to those found in free carboxylic acids, showing that there is very little, if any, negative charge located on the oxygen atoms that are not bonded to titanium. In 1 the chloride–titanium–chloride angle is 95.98, which is in the range of other titanocene dichlorides. In 1, however, the oxygen atoms are part of a chelate ring which forces the oxygen–titanium–oxygen angle to 79.08. Despite the addition of the bidentate oxalate ligand. minimal structural change incurred. In tests against LLC-PK cells, which have proven to be a valuable in vitro model for kidney cancer, titanocene oxalate shows an IC50 value of 140 mm, which is a significant improvement (14-fold) relative to titanocene dichloride, with an IC50 value of 2000 mm. Similar behaviour is observed for the p-dimethoxybenzyl-substituted species; 2 is 13-fold more cytotoxic against LLC-PK than 1 and exhibits an IC50 value of 1.6 mm (see Figure 2), which is twice as cytotoxic as cisplatin (3.3 mm). The Scheme 1. Structures and syntheses of titanocene Y (1) and oxali-titanocene Y (2): a) 2LiBEt3H, Et2O, 2BEt3 ; b) TiCl4, THF, 2LiCl(s) ; c) Ag2C2O4, THF, 2AgCl(s).

James Claffey

Papers

Synthesis, Cytotoxicity and Antibacterial Studies of p-Methoxybenzyl-Substituted and Benzyl-Substituted N-Heterocyclic Carbene-Silver Complexes

Novel organotin antibacterial and anticancer drugs

Oxali-titanocene Y: a potent anticancer drug.

Proliferative and anti-proliferative effects of titanium- and iron-based metallocene anti-cancer drugs

Analyses of Titanocenes in the spheroid-based cellular angiogenesis assay.